Clinical trial · Interventional
89Zr-labeled NY008 PET Imaging in Patients
NCT05655676CI-TRIAL-00062743unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY008 PET Imaging in patients with multiple myeloma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 89Zr-NY008 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 89Zr-NY008
- interventionNames
- Drug: 89Zr-NY008
Primary outcomes (1)
- measure
- Evaluation of tissue distribution of 89Zr-NY008
- timeFrame
- 7 days
- description
- Biodistribution of 89Zr-NY008 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs will be reported.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Older than 18 years old, male or female; 2. Patients diagnosed with relapsing or refractory multiple myeloma; 3. LVEF≥50%; 4. ECOG score 0\~2; Exclusion Criteria: 1. Life expectancy of less than 3 months; 2. Participated in other clinical research within 1 month; 3. Recovery from major trauma (including surgery) within 28 days prior to study treatment; 4. Patients with systemic or locally severe infections, or other serious coexisting diseases; 5. Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; 6. Patients with autoimmune diseases, including rheumatoid arthritis; 7. Inadequate control of arrhythmias, including atrial fibrillation; 8. Uncontrolled hypertension; 9. Patients with allergies or allergies to any component of the imaging agent or antibody; 10. Patients who cannot undergo PET/CT imaging scan; 11. Syphilis, HBV, HCV, or HIV positive subjects; 12. Male and female subjects of reproductive age cannot take effective contraceptive measures; 13. Pregnant or lactating women; 14. Patients with a history of mental illness or related conditions; 15. Other subjects considered unsuitable by researchers.
References
Publications (0)
Data not yet available
No reference posted for this study.